Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FGLM-NH2 + SSSR peptides
- Development stage
- Unknown
- Lead developer
- Yamaguchi University Graduate School of Medicine
- Modality
- Peptides
- Administration
- Ophthalmic
01
Overview
FGLM-NH2 + SSSR is a combination peptide ophthalmic solution designed to treat neurotrophic keratopathy, particularly in patients with leprosy sequelae. FGLM-NH2 is a tetrapeptide (Phe-Gly-Leu-Met-NH2) derived from the C-terminus of Substance P, while SSSR is a tetrapeptide (Ser-Ser-Ser-Arg) derived from the cell-binding domain of fibronectin. Together, they act synergistically to stimulate corneal epithelial cell migration and attachment, facilitating the repair of persistent epithelial defects caused by trigeminal nerve damage. The therapy was developed through research at Yamaguchi University and has been evaluated in clinical trials sponsored by Japanese medical research funds, demonstrating significant efficacy in healing corneal epithelial defects and increasing corneal thickness.
- Other names
- FGLM-NH2 + SSSR peptides ophthalmic solutionSubstance P-derived peptide + fibronectin-derived peptideFGLM-NH2/SSSR
02
Targets
TACR1 (Neurokinin‑1 Receptor)SSTR (Somatostatin receptors)
Beyond the preview
Go deeper on FGLM-NH2 + SSSR peptides.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FGLM-NH2 + SSSR peptides.